EU Health PPP: a new era for medtech companies
Posted on 11.05.2021
For decades, companies in the medtech and pharma sectors have delivered healthcare innovations separately – collaboration has been limited. However, we know that this is not how patients experience healthcare. In the real world, diagnostics, devices, medicines, vaccines and digital tools combine to keep people healthy and to treat those who are unwell.
This reality is reflected in the new EU PPP for Health which will launch next year. It is the successor to the Innovative Medicines Initiative (IMI) – a public-private partnership between the European Commission and the research-based pharmaceutical industry.